Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Berkshire Hathaway Inc Class B — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Berkshire Hathaway Inc Class B trades at $496.15. Which is the better fit depends on your goals.
| ACAD | BRK.B | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Financials |
52-Week High | $28.06 | $513.70 |
52-Week Low | $20.06 | $459.10 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Berkshire Hathaway Class B shares (BRK.B) trade at $495.03, down 2.3% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong institutional support and a positive analyst consensus, though key valuation metrics like P/E and P/B are not provided in the current data. Recent business performance reflects the company's diversified holdings and steady cash flow generation.
The outlook remains favorable given analyst buy ratings and technical strength, but risks include market volatility and economic sensitivity. Investment opportunity lies in Berkshire's resilient portfolio, while caution is warranted near current resistance levels. The stock's trajectory hinges on broader market conditions and internal capital allocation decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
